Mangoceuticals announces obtaining DEA authorization for the company’s groundbreaking HIPAA-compliant operating system through Surescripts. This significant milestone positions MangoRx at the forefront of the direct-to-consumer, DTC, telemedicine market. Securing DEA clearance to prescribe controlled medications via Surescripts, the nation’s leading health information network, sets MangoRx apart from its competitors, validating its cutting-edge technology and regulatory compliance. This approval aims to give MangoRx’s provider network more flexibility in prescribing custom medication and treatments to include a comprehensive range of controlled substances such as hormone replacement therapies – which they anticipate will drive significant growth in this category. The DEA approval provides a robust foundation for the company’s future expansion and success, ensuring adherence to stringent regulatory standards while fostering innovation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGRX:
- MangoRx Secures DEA Approval for Proprietary HIPAA-Compliant Operating System via Surescripts
- MangoRx Appoints Dr. Douglas Christianson, N.D. as Director of the Medical Research and Product Innovation Department
- MangoRx Announces Strategic Partnership for Expansion into Asia Pacific and Key Emerging Markets
- Mangoceuticals announces partnership with ISFLST
- Mangoceuticals receives Notice of Acceptance for patent application in Australia